CRVO CervoMed Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1053691 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.9%
TTM net income YoY-11.5%
TTM EPS YoY—
Revenue 3-yr CAGR-87.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-334,924.9%
Net margin-326,822.5%
FCF margin—
EBITDA margin—
Returns
ROE-131.5%
ROA-109.8%
ROIC (approx.)-165.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $8,726 | $322,569 | $1.76M | $1.92M | $2.16M |
| R&D expense | $3.68M | $4.32M | $5.14M | $5.83M | $6.04M | $5.11M | $4.84M | $7.09M |
| SG&A expense | $2.43M | $2.36M | $2.98M | $2.51M | $2.33M | $3.27M | $2.38M | $2.32M |
| Operating income | -$6.10M | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | -$5.30M | -$7.24M |
| Net income | -$5.90M | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | -$4.89M | -$6.71M |
| EPS (basic) | -0.39 | -0.64 | -0.86 | — | -0.84 | -0.70 | -0.56 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.06M | $22.46M | $7.94M | $8.24M | $9.44M | $8.32M | $10.50M | $9.00M |
| Short-term investments | $13.54M | $2.48M | $4.98M | $12.63M | $17.86M | $25.21M | $24.74M | $29.92M |
| Current assets | $21.33M | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | $38.58M | $43.08M |
| Total assets | $21.33M | $25.99M | $15.11M | $22.88M | $30.61M | $38.08M | $38.58M | $43.08M |
| Current liabilities | $3.97M | — | — | $4.66M | — | — | — | $3.88M |
| Total liabilities | $3.97M | $3.03M | $4.50M | $4.66M | $4.60M | $4.64M | $3.94M | $3.88M |
| Shareholders' equity | $17.36M | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | $34.63M | $39.20M |
| Shares outstanding | 15.12M | 13.53M | 9.26M | 9.25M | 9.25M | 9.25M | 8.70M | 8.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.07M | -$6.92M | -$8.02M | -$6.58M | -$6.47M | -$6.51M | -$3.89M | -$8.05M |
| Investing cash flow | -$10.97M | $2.53M | $7.71M | $5.37M | $7.58M | -$254,993 | $5.40M | $9.31M |
| Financing cash flow | -$357,921 | $18.91M | $13,800 | $0 | $0 | $4.59M | $0 | $0 |
| Stock-based compensation | $307,445 | $362,275 | $349,196 | $298,735 | $291,717 | $497,015 | $361,167 | $337,711 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.